Infertility Drugs Market is projected to reach US$ 6,814.68 million by 2033 | FMI
Infertility affects both men and
women equally. The causes of female infertility include growing older, polycystic
ovarian syndrome (PCOS), obesity, and miscarriages. While the causes of male
infertility include erectile dysfunction, low sperm count, abnormal sperm, and
others. The BGU developed a new treatment that re-lengthens telomeres to
protect cells by stimulating telomerase expression.
Get Full Access @ https://www.futuremarketinsights.com/reports/infertility-drugs-market
For treating infertility, market
players are focused on introducing novel medications. A firm is currently
developing the first-in-class OXO-001 product candidate, which is expected to
enhance the binding of embryos to the inner lining of the uterus by increasing
binding strength. In addition, Ferring Pharmaceuticals has recently launched a
novel fertility treatment for women, Trisequens.
Key Takeaways from Market Study
- The infertility drugs market is expected to record a
CAGR of 6.3% over the forecast period.
- According to estimates, the infertility drugs market in
North America may remain strong throughout the length of the forecast
period.
- The gonadotropins segment dominated the infertility
drugs market with a revenue share of 40.1% in 2023 and is expected to grow
rapidly.
- The women’s segment dominated the market for
infertility drugs in 2023 with a revenue share of 71.3%.
Competitive Landscape:
Several prominent companies dominate
this market, including Ferring Pharmaceuticals Inc., Merck KGaA, Bayer
AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Theramex, Novartis AG.,
Abbott Laboratories, Bayer AG, Novartis AG, Merck & Co., Inc., Pfizer,
Inc., Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Ferring Holdings SA,
Organon & Co., Mankind Pharma Ltd., and others.
Sustainable and environmental footprint
awareness may drive the choice of active ingredients and materials for the
Infertility Drug Market, as well as packaging. By engaging in these activities,
manufacturers can expand their product portfolios, expand their geographical
reach, and capture a larger share of the market.
In addition to gaining access to the
latest markets and advanced technologies, key players can also gain access to
new markets by partnering with other companies. In addition, companies can
acquire, merge, and diversify their portfolios.
Recent Developments:
- Genea Biomedx (Australia) partnered with Hamilton
Thorne in 2020 to sell its fertility products in the United States and
Canada.
- The Pergoveris Pen is the first pen injector for
gonadotropins, which are hormones that play a crucial role in reproduction
and fertility. It was introduced to India in August 2021 by Merck, to
treat infertility.
- The Fertility Partners, the leading provider of
fertility services in Canada, has partnered with Maven Clinic to form a
referral network for fertility clinics. Maven's network helps its members
find high-quality fertility care in over 70 countries. The company also
launched MavenRx, its new medication service, in February 2020, to help
fertility members get their medications more seamlessly.
Infertility Drugs Market
Segmentation by Category
By Drug Class:
- Gonadotrophins
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Biguanides
- Other Drug Classes
By End User:
- Male
- Female
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Other Distribution Channels
Comments
Post a Comment